Expert Opinion on Investigational Drugs [ISSN 1354-3784]; [e-ISSN 1744-7658] is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles and original papers on drugs in preclinical and early-stage clinical development, providing expert opinion on the scope for future development. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development.
Expert Opinion on Investigational Drugs address the needs of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.
The Editors welcome:
- Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies.
- Drug Evaluations reviewing the clinical and pharmacological data on a particular drug.
- Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials.
Please note that we do not consider case report or case series articles.
Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections:
Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results;
Article Highlights – an executive summary of the author’s most critical points.
Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees.
Reach an international clinical and medical audience alongside other key option leaders in your field by publishing with Expert Opinion on Investigational Drugs, part of the Expert Collection brand.
For any pre-submission enquiries, please contact the Commissioning Editor.
EDITOR-IN-CHIEF
Dr. Naim Alkhouri, Texas Liver Institute, San Antonio, TX, USA
ASSOCIATE EDITORS
Dr. Jerry Colca, Kalamazoo Metabolic Research, Kalamazoo, MI, USA
EDITOR-IN-CHIEF EMERITUS
Prof. Giuseppe Tonini, University Campus Bio-Medico, Rome, Italy
EDITORIAL ADVISORY BOARD
Prof. Karl-Eric Andersson, Wake Forest University, Winston-Salem, NC, USA
Prof. Wilbert Aronow, New York Medical College, Valhalla, NY, USA
Prof. Guglielmo Borgia, University of Naples Federico II, Napoli, Italy
Dr. Martin Braddock, AstraZeneca, Loughborough, England, UK
Prof. Maria Luisa Brandi, Vita-Salute University at the San Raffaele, Milan, Italy
Prof. Linda Cardozo, King's College London, London, England, UK
Prof. Thomas Ciulla, Indiana University School of Medicine, Indianapolis, IN, USA
Prof. Mellar Davis, Taussig Cancer Institute, Cleveland, OH, USA
Prof. William Denny, University of Auckland, Auckland, New Zealand
Dr. Nafsika Georgopapadakou, NHG LLC, Princeton, NJ, USA
Dr. Lars Grundemar, Ferring Pharmaceuticals, Copenhagen, Denmark
Prof. Percy Ivy, National Cancer Institute, Bethesda, MD, USA
Prof. Michael Koutsilieris, University of Athens, Athens, Greece
Prof. Renu Kowluru, Wayne State University, Detroit, MI, USA
Prof. Dimitri Mikhalidis, University College London, London, UK
Prof. Nouri Naemati, University of Southern California, Los Angeles, CA, USA
Prof. Athanasios Papatsoris, University of Athens, Athens, Greece
Prof. Athanasios Papavassiliou, University of Athens, Athens, Greece
Prof. Godefridus J. Peters, Amsterdam UMC, Amsterdam, The Netherlands
Dr. Alessandro Rizzo, S. Orsola-Malpighi University Hospital, Bologna, Italy
Prof. Marwan N Sabbagh, Banner Sun Health Research Institute, Sun City, AZ, USA
Dr. Tomi Sawyer, Merck Research Laboratories, Boston, MA, USA
Prof. Nicola Silvestris, University of Messina, Messina, Italy
Dr. Noel J Snell, Royal Brompton Hospital, London, UK
Dr. Guru Sonpavde, Dana Farber Cancer Institute, Boston, MA, USA
Prof. Christoph Stein, Charité Campus Benjamin Franklin, Berlin, Germany
Prof. Eleftherios Tsiridis, Imperial College, London, UK
Prof. László Vecsei, University of Szeged, Szeged, Hungary
Prof. Stephan von Haehling, University of Göttingen, Göttingen, Germany
Dr. Robert Williams, Cancer Research, London, UK
Expert Opinion on Investigational Drugs is a hybrid open access journal that is part of our Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
If you choose to publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis.
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/110817/Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
![HRB Open Research is a platform for HRB-funded researchers to rapidly publish their research outputs in an open and accessible way.]({"type":"image" , "src" : "/sda/112432/HRB-KB.jpg"})